Carrick Therapeutics lands $35m investment from Pfizer
Dublin-based biopharma firm has received investment to support the rapid development of its flagship drug samuraciclib which is used in the treatment of HR+, HER2- breast cancer
Carrick Therapeutics, a Dublin-headquartered biopharma firm, has landed a $35 million investment from Pfizer as it also confirmed the final closure of a $25 million Series C funding round.
The company which is developing pioneering treatments to defeat some of the most aggressive cancers was founded by Elaine Sullivan, a former vice-president for research and development at both Eli Lilly and AstraZeneca, in 2016.
Carrick said on Thursday it has received investment from Pfizer to ...